Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors

Modern Pathology

Volumn 29, Issue 11, 2016, Pages 1335-1346

  Lee, Jen Chieh ^a   Su, Sheng Yao ^b,c   Changou, Chun A ^d   Yang, Rong Sen ^a   Tsai, Keh Sung ^a   Collins, Michael T ^e   Orwoll, Eric S ^f   Lin, Chung Yen ^b   Chen, Shu Hwa ^b   Shih, Shyang Rong ^a   Lee, Cheng Han ^g   Oda, Yoshinao ^h   Billings, Steven D ⁱ   Li, Chien Feng ^j   Nielsen, G Petur ^k   Konishi, Eiichi ^l   Petersson, Fredrik ^m   Carpenter, Thomas O ⁿ   Sittampalam, Kesavan ^o   Huang, Hsuan Ying ^p   Folpe, Andrew L ^q   more..

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b INSTITUTE OF INFORMATION SCIENCE   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g UNIVERSITY OF ALBERTA   (Canada)

^h KYUSHU UNIVERSITY   (Japan)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

^j CHI MEI MEDICAL CENTER   (Taiwan)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^m NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

ⁿ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o SINGAPORE GENERAL HOSPITAL   (Singapore)

^p CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^q MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBRONECTIN; FIBRONECTIN 1; GENOMIC DNA; MESSENGER RNA PRECURSOR; UNCLASSIFIED DRUG; FGFR1 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 23; FN1 PROTEIN, HUMAN; ONCOPROTEIN;

ARTICLE; CHONDROBLASTOMA; CONTROLLED STUDY; EXON; FIBROMA; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE IDENTIFICATION; GENE INSERTION; GENE SEQUENCE; GIANT CELL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRACELLULAR SIGNALING; INTRON; LIGAND BINDING; MESENCHYMOMA; MOLECULAR PATHOLOGY; MOLECULAR WEIGHT; OSSIFYING FIBROMA; OSTEOBLASTOMA; OSTEOSARCOMA; PHOSPHATURIA; PREVALENCE; PRIORITY JOURNAL; RNA SEQUENCE; SEQUENCE ANALYSIS; SOLITARY FIBROUS TUMOR; BONE TUMOR; GENETICS; SECRETION (PROCESS); SOFT TISSUE TUMOR;

BONE NEOPLASMS; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTORS; FIBRONECTINS; HUMANS; ONCOGENE PROTEINS, FUSION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SOFT TISSUE NEOPLASMS;

EID: 84979256639     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2016.137     Document Type: Article

References (46)

1. Folpe AL. Phosphaturic mesenchymal tumourIn: Fletcher CDM, Bridge JA, Hogendoorn PCW et al. eds World Health Organization Classification of Tumours of Soft Tissue and Bone. IARC Press: Lyon, France, 2013;2.
2. Folpe AL, Fanburg-Smith JC, Billings SD et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 2004;28:1-30.
3. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001;98:6500-6505.
4. White KE, Larsson TE, Econs MJ. The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23. Endocr Rev 2006;27:221-241.
5. Berndt T, Craig TA, Bowe AE et al. Secreted frizzledrelated protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 2003;112:785-794.
6. Rowe PS, de Zoysa PA, Dong R et al. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 2000;67:54-68.
7. Habra MA, Jimenez C, Huang SC et al. Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia. Endocr Pract 2008;14: 1108-1114.
8. Lee JC, Jeng YM, Su SY et al. Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour. J Pathol 2015;235: 539-545.
9. Bowe AE, Finnegan R, Jan de Beur SM et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 2001;284:977-981.
10. Carter JM, Caron BL, Dogan et al. A novel chromogenic in situ hybridization assay for FGF23 mRNA in phosphaturic mesenchymal tumors. Am J Surg Pathol 2015; 39:75-83.
11. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009;25:1105-1111.
12. Anders S, McCarthy DJ, Chen Y et al. Count-based differential expression analysis of RNA sequencing data using R and Bioconductor. Nat Protoc 2013;8: 1765-1786.
13. Lee JC, Lu TP, Changou CA et al. Genomewide copy number analysis of Müllerian adenosarcoma identified chromosomal instability in the aggressive subgroup. Mod Pathol; advance online publication, 3 June 2016; doi:10. 1038/modpathol. 2016. 99 (e-pub ahead of print).
14. Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer 1987;59:1442-1454.
15. Dorfman HD, Czerniak B. Bone Tumors. Mosby: St Louis, MO, USA, 1998.
16. Jackson CC, Medeiros LJ, Miranda RN. 8p11 myeloproliferative syndrome: a review. Hum Pathol 2010;41: 461-476.
17. Ren H, Tan ZP, Zhu X et al. Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer. Cancer Res 2012;72:3312-3323.
18. Lovly CM, Gupta A, Lipson D et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov 2014;4: 889-895.
19. el-Hariry I, Pignatelli M, Lemoine N. Fibroblast growth factor 1 and fibroblast growth factor 2 immunoreactivity in gastrointestinal tumours. J Pathol 1997;181:39-45.
20. Chow NH, Cheng KS, Lin PW et al. Expression of fibroblast growth factor-1 and fibroblast growth factor-2 in normal liver and hepatocellular carcinoma. Dig Dis Sci 1998;43:2261-2266.
21. Smith J, Yelland A, Baillie R et al. Acidic and basic fibroblast growth factors in human breast tissue. Eur J Cancer 1994;30A:496-503.
22. Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004;11:709-724.
23. Ornitz DM, Xu J, Colvin JS et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996;271:15292-15297.
24. Gospodarowicz D, Handley HH. Stimulation of division of Y1 adrenal cells by a growth factor isolated from bovine pituitary glands. Endocrinology 1975;97: 102-107.
25. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8:235-253.
26. Imamura T, Engleka K, Zhan X et al. Recovery of mitogenic activity of a growth factor mutant with a nuclear translocation sequence. Science 1990;249: 1567-1570.
27. Wesche J, Malecki J, Wiedlocha et al. Two nuclear localization signals required for transport from the cytosol to the nucleus of externally added FGF-1 translocated into cells. Biochemistry 2005;44:6071-6080.
28. Singh P, Carraher C, Schwarzbauer JE. Assembly of fibronectin extracellular matrix. Annu Rev Cell Dev Biol 2010;26:397-419.
29. Quade BJ, McDonald JA. Fibronectin's amino-terminal matrix assembly site is located within the 29-kDa amino-terminal domain containing five type I repeats. J Biol Chem 1988;263:19602-19609.
30. Wu ZL, Zhang L, Yabe T et al. The involvement of heparan sulfate (HS) in FGF1/HS/FGFR1 signaling complex. J Biol Chem 2003;278:17121-17129.
31. Brown A, Robinson CJ, Gallagher JT et al. Cooperative heparin-mediated oligomerization of fibroblast growth factor-1 (FGF1) precedes recruitment of FGFR2 to ternary complexes. Biophys J 2013;104:1720-1730.
32. Nieto L, Canales A, Fernandez IS et al. Heparin modulates the mitogenic activity of fibroblast growth factor by inducing dimerization of its receptor. A 3D view by using NMR. Chembiochem 2013;14:1732-1744.
33. Puls F, Hofvander J, Magnusson L et al. FN1-EGF gene fusions are recurrent in calcifying aponeurotic fibroma. J Pathol 2016;238:502-507.
34. Jeon E, Kim HW, Jang JH. Protein engineering of a fibroblast growth factor-1 fusion protein with cell adhesive activity. Acta Biochim Biophys Sin (Shanghai) 2009;41:852-857.
35. Brownstein CA, Adler F, Nelson-Williams C et al. A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci USA 2008;105:3455-3460.
36. Nabeshima Y. Klotho: a fundamental regulator of aging. Ageing Res Rev 2002;1:627-638.
37. White KE, Cabral JM, Davis SI et al. Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet 2005;76: 361-367.
38. Liu S, Tang W, Fang J et al. Novel regulators of Fgf23 expression and mineralization in Hyp bone. Mol Endocrinol 2009;23:1505-1518.
39. Martin A, Liu S, David V et al. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J 2011;25: 2551-2562.
40. Wu AL, Feng B, Chen MZ et al. Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia. PLoS One 2013;8:e57322.
41. Xiao Z, Huang J, Cao L et al. Osteocyte-specific deletion of Fgfr1 suppresses FGF23. PLoS One 2014;9:e104154.
42. Yavropoulou MP, Gerothanasi N, Frydas et al. Tumorinduced osteomalacia due to a recurrent mesenchymal tumor overexpressing several growth factor receptors. Endocrinol Diabetes Metab Case Rep 2015;2015: 150025.
43. Bahrami A, Weiss SW, Montgomery E et al. RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia. Am J Surg Pathol 2009;33:1348-1354.
44. Doyle LA, Vivero M, Fletcher CD et al. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol 2014;27: 390-395.
45. Behjati S, Tarpey PS, Presneau N et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 2013;45: 1479-1482.
46. Rosenbloom KR, Armstrong J, Barber GP et al. The UCSC Genome Browser database: 2015 update. Nucleic Acids Res 2015;43:D670-D681.